European Neuropsychopharmacology

Do antipsychotics provoke depression?
pp. 96-96(1)
Author: Kasper S.

Beta- and gamma-secretases: Could they be seen as therapeutic molecular targets
pp. 96-97(2)
Author: Checler F.

Can we predict the development of Alzheimer's disease through mild cognitive impairment
pp. 97-97(1)
Authors: Hanninen T.; Soininen H.

An immunotherapeutic approach to the treatment of Alzheimer's disease
pp. 97-98(2)
Authors: Seubert P.; Games D.; Bard F.; Yednock T.; Schenk D.

The inflammatory hypothesis of Alzheimer's disease: Where do we stand?
pp. 98-99(2)
Author: Eikelenboom P.

Long-term effects and prevention of Alzheimer's disease with cholinergic treatment
pp. 99-100(2)
Author: Giacobini E.

Receptor models of inverse agonism
pp. 103-104(2)
Author: Onaran H.O.

Inverse agonism at beta-adrenergic receptors
pp. 104-104(1)
Author: Gurdal H.

Genetics and efficacy in depression
pp. 105-105(1)
Authors: Mendlewicz J.; Souery D.

The efficacy of hypericum: Does severity matter?
pp. 105-106(2)
Author: Lecrubier Y.

Different efficacy of antidepressants in inpatients with depression
pp. 106-107(2)
Authors: Nolen W.A.; Bruijn J.A.

Management strategies in melancholia
pp. 107-108(2)
Author: Parker G.

Antipsychotics and disruptive disorders in children
pp. 112-112(1)
Author: Aman M.G.

Treatment of ADHD: Evidence from placebo-controlled studies
pp. 112-112(1)
Author: Taylor E.

Control of neurosteroid biosynthesis by neurotransmitters and neuropeptides
pp. 112-113(2)
Authors: Do-Rego J.L.; Tonon M.C.; Luu-The V.; Pelletier G.; Vaudry H.

Neurosteroids: Functional aspects
pp. 113-114(2)
Authors: Vallee M.; Mayo W.; Le Moal M.

Neurosteroids, role in brain function: Neuroprotective effects, memory, ageing
pp. 114-114(1)
Author: Baulieu E.E.

Neurosteroids as a brain target for sex steroids
pp. 115-115(1)
Authors: Genazzani A.R.; Quirici B.; Russo T.; Pieri M.; Stomati M.

Interactions between serotonin and dopamine in the basal ganglia
pp. 118-119(2)
Authors: Spampinato U.; Porras G.; De Deurwaerdere P.

Need for and problems with placebo-controlled studies
pp. 119-119(1)
Author: Fleischhacker W.W.

Are atypicals better than antipsychotics in long-term schizophrenia?
pp. 119-120(2)
Author: Moller H.-J.

Atypical antipsychotics in relapse prevention, evidence by controlled studies
pp. 120-120(1)
Author: Naber D.

Relapse criteria for schizophrenia
pp. 120-122(3)
Author: De Smedt G.

MRI anatomy of schizophrenia: A review and update
pp. 122-122(1)
Author: McCarley R.

Alcohol abuse, schizophrenia, and atypical antipsychotics
pp. 124-125(2)
Authors: Citrome L.; Volavka J.

Neurosteroids and alcohol action
pp. 125-126(2)
Authors: Barbaccia M.L.; Gessa G.L.

The role of NMDA receptor systems in alcohol reward
pp. 126-127(2)
Authors: Bespalov A.Y.; Zvartau E.E.

Gene expression profiling of psychiatric disorders: Perspectives from regional and single cell analysis
pp. 127-128(2)
Author: Hemby S.E.

Dopamine signalling and downstream targets
pp. 128-129(2)
Authors: Oak J.; Kotecha S.; MacDonald J.F.; Van Tol H.H.M.

PPARs: Three isotypes for multiple functions
pp. 129-129(1)
Authors: Wahli W.; Basu-Modak S.; Michalik L.; Tan N.S.; Braissant O.; Honegger P.; Desvergne B.

Typical and atypical antipsychotics in the treatment of mania
pp. 132-132(1)
Author: Goodwin G.M.

Treatment of mixed episodes
pp. 132-133(2)
Author: Sachs G.S.

Schizophrenia and autonoetic awareness
pp. 133-134(2)
Authors: Danion J.-M.; Huron C.; Robert P.

Discriminant cognitive factors according to treatment response and to antipsychotic drugs in patients with schizophrenia: Issues on practice effect, dosing, D₂ occupancy, and procedural learning
pp. 134-135(2)
Author: Stip E.

Is this possible to predict cognitive effects of antipsychotics according to their pharmacological profile?
pp. 136-136(1)
Author: Benoit M.

Efficacy of new antipsychotics on cognitive functions in schizophrenia
pp. 136-137(2)
Author: Peuskens J.

Nicotine withdrawal and antidepressants: Serotonergic modulation of reward
pp. 140-141(2)
Author: Markou A.

Functional genomics of the GPCR family: Identification of novel drug targets for CNS diseases and pain control
pp. 141-141(1)
Authors: Walker P.; Lembo P.; O'Donnell D.; Groblewski T.; Hoffert C.; Grazzini E.; Pelletier M.; Schmidt R.; Duchesne M.; Payza K.; Gawell L.; Ahmad S.

The role of MCH functions in CNS: Food intake and stress
pp. 141-142(2)
Author: Hervieu G.

Orphanin-FQ/nociceptin: Role in modulating fear/anxiety states in rodents
pp. 142-143(2)
Authors: Ouagazzal A.M.; Moreau J.-L.; Jenck F.

Mammalian G protein-coupled receptors for RFamide ligands
pp. 143-144(2)
Author: Evans J.F.

Treatment of depression and other emotional disturbances in the elderly
pp. 144-144(1)
Author: Gottfries C.G.

Treatment of posttraumatic stress disorder - an update
pp. 147-148(2)
Authors: Zohar J.; Amital D.; Sasson Y.; Amitai K.; Zinger Y.

Natural course of PTSD and its long-term treatment
pp. 148-149(2)
Authors: Davidson J.R.T.; Connor K.M.

Brain development in childhood-onset schizophrenia: Progressive cortical loss in adolescence
pp. 149-150(2)
Authors: Rapoport J.; Giedd J.; Castellanos X.

BDNF, behavioral sensitization and schizophrenia
pp. 150-150(1)
Authors: Guillin O.; Diaz J.; Carroll P.; Griffon N.; Schwartz J.-C.; Sokoloff P.

Brain structure changes across the lifespan of schizophrenia: Excessive gray matter changes in schizophrenia
pp. 151-151(1)
Authors: Hulshoff Pol H.E.; Kahn R.S.

Animal models on schizophrenia as a neurodevelopmental disorder
pp. 152-153(2)
Authors: Gerrits M.A.F.M.; Wolterink G.; Daenen E.W.P.M.; Van Ree J.M.

Venlafaxine in treatment of GAD
pp. 157-158(2)
Authors: Salinas E.O.; Hackett D.

Efficacy of selective serotonin reuptake inhibitors in generalised anxiety disorder
pp. 158-158(1)
Author: Baldwin D.

Deramciclane in GAD
pp. 159-159(1)
Author: Montgomery S.A.

Pregabalin, a novel agent in the treatment of anxiety disorders
pp. 159-160(2)
Authors: Lydiard R.B.; Feltner D.E.; Robinson P.; Liu-Dumaw M.; Pande A.C.; Pregabalin Anxiety Disorders Trials Groups

Long-term efficacy in GAD
pp. 160-161(2)
Author: Lader M.

Double-blind studies in severe Alzheimer's disease
pp. 161-161(1)
Author: Vellas B.

Reperfusion injury: Endothelial/vascular targets
pp. 163-164(2)
Authors: Dalkara T.; Gursoy-Ozdemir Y.; Can A.

Caspases and ischemic cell death: Mechanisms and treatment
pp. 164-165(2)
Author: Moskowitz M.A.

The neuropeptide galanin: A modulator of 5-HT_1A receptor mechanisms of relevance for affective disorders
pp. 168-169(2)
Authors: Ogren S.O.; Razani H.; Kehr J.; Fuxe K.; Diaz-Cabiale Z.; Misane I.

The psychopathological status of depressive symptoms in schizophrenia
pp. 169-170(2)
Author: D'haenen H.

Depressive symptoms and cognitive impairment in the context of prodromal and first episode schizophrenia
pp. 170-170(1)
Author: Davidson M.

Atypical antipsychotics on depressive symptoms in schizophrenia
pp. 170-171(2)
Author: Cookson J.

Long term management of social anxiety disorder
pp. 171-171(1)
Author: Stein D.J.

Stress and brain nitric oxide
pp. 175-176(2)
Author: Leza J.C.

NO and regulation of NMDA receptor function
pp. 176-177(2)
Author: Lipton S.A.

The 5-HT1B receptor as a novel target. Is there a role for endogenous modulating factor?
pp. 177-178(2)
Authors: Fillion G.; Massot O.; Grimaldi B.; Bourin M.S.

AR-A000002, a novel 5-HT_1B selective antagonist with antidepressant potential
pp. 178-179(2)
Author: Stenfors C.

CRF₁ receptor antagonists: Long term treatment and efficacy in animal models
pp. 179-180(2)
Authors: Owens M.J.; Gutman D.A.

Repeated imipramine, 8-OH-DPAT and corticosterone alter postsynaptic but not presynaptic 5-HT_1A receptor sensitivity
pp. 184-185(2)
Authors: Zahorodna A.; Gadek-Michalska A.; Bijak M.

Sertraline in PTSD: Sequence of response
pp. 185-185(1)
Authors: Davidson J.R.T.; Farfel G.; Clary C.M.; Landerman L.R.

Preclinical antidepressant profile of AR-A2XX, a novel 5-HT_1B antagonist
pp. 185-186(2)
Authors: Hudzik T.J.; Yanek M.; Porrey T.; Evenden J.; Mastrangelo M.; Ryan C.; Ross S.; Stenfors C.

Mirtazapine's onset of action compared with SSRIs: Response and remission rates
pp. 186-186(1)
Authors: Van Oers H.J.J.; Schutte A.J.

Mirtazapine vs SSRIs: Onset of therapeutic effect using a survival analysis approach (Kaplan-Meier analysis)
pp. 186-186(1)
Authors: Schutte A.J.; Van Oers H.J.J.

Effects of venlafaxine/venlafaxine XR and selective serotonin reuptake inhibitors on suicidal ideation
pp. 188-189(2)
Authors: Entsuah R.; Cantillon M.

Nefazodone in the treatment of depression: Efficacy and tolerability data from a prospective open clinical trial
pp. 189-189(1)
Authors: Ulug B.; Ozerdem A.; Oral E.T.; Karaagaoglu E.; Gogus A.

Behavioural response of gerbils to anxiolytics and antidepressants in the light and dark test
pp. 189-190(2)
Authors: Lapiz M.D.S.; Hogg S.

Sertraline versus fluvoxamine in the treatment of elderly depressed patients: A double-blind randomized trial
pp. 190-190(1)
Authors: Rossini D.; Franchini L.; Smeraldi E.; Zanardi R.

Borderline personality disorder in early- and late-onset bipolar II disorder
pp. 190-191(2)
Author: Benazzi F.

Fluoxetine for maintenance of recovery from depression in children and adolescents: A placebo-controlled, randomized clinical trial
pp. 192-193(2)
Authors: Emslie G.; Heiligenstein J.; Hoog S.; Ernest D.; VanHooy B.; Brown E.; Jacobson J.

Patient and rater education of expectations in clinical trails (PREECT): An approach to reducing placebo response rates in acute depression trials
pp. 193-193(1)
Authors: Zimbroff D.L.; Mendez G.

Dysthymic disorder: Treatment with citalopram
pp. 193-193(1)
Authors: Dunner D.L.; Hendrickson H.E.; Bea C.; Budech C.; Friedman S.

Fluoxetine versus placebo in posttraumatic stress disorder
pp. 193-194(2)
Authors: Martenyi F.; Brown E.; Zhang H.; Prakash A.; Koke S.

Validation and assessment of practical use of a self-rating scale for axis-I disorders (PRIME-MD TODAY) in general hospitals
pp. 194-194(1)
Authors: Fischler B.; Persoons P.; Luyckx K.; Vander Mijnsbrugge D.

Alpha-1-acid glycoprotein, age and melancholic subtype in female depressed patients
pp. 194-195(2)
Authors: Nieto E.; Vieta E.; Alvarez L.; Autet A.; Gasto C.

Global benefit-risk comparison of venlafaxine/venlafaxine XR, selective serotonin reuptake inhibitors, and placebo
pp. 197-197(1)
Authors: Entsuah R.; Gao B.

Venlafaxine and selective serotonin reuptake inhibitors in depression: Comparison among age and gender variables
pp. 197-197(1)
Authors: Entsuah R.; Cantillon M.; Thase M.

Evidence that fluoxetine reduces in vivo levels of central voltammetric nitrogen monoxide: Another antidepressant mechanism of selective serotonin reuptake inhibitors (SSRIs)?
pp. 197-198(2)
Authors: Crespi F.; Lazzarini E.; Vecchiato E.; Bianchi C.M.; Corsi M.

Light therapy to thirty-four bipolar patients with and without lithium
pp. 198-198(1)
Authors: Van Gent E.M.; Keegstra H.J.; Barents W.

Medicative and preventive effects of enterosorbent noolit on anxious-depressive state in male mice
pp. 198-199(2)
Authors: Borodin J.I.; Tenditnik M.V.; Kudryavtseva N.N.; Rachkovskaya L.N.; Shurlygina A.V.; Trufakin V.A.

Influence of the angiotensin I converting enzyme gene I/D polymorphism on response to partial sleep deprivation in major depression
pp. 199-199(1)
Authors: Baghai T.C.; Schule C.; Zwanzger P.; Minov C.; Schwarz M.J.; De Jonge S.; Zill P.; Rupprecht R.; Bondy B.

Treatment of acute manic and mixed episodes with open-label risperidone
pp. 201-201(1)
Authors: Nimatoudis I.; Kaprinis G.; Fountoulakis K.N.

Cognitive functions in remitted patients with major depressive disorder during prophylactic treatment
pp. 201-202(2)
Authors: Jaracz J.; Borkowska A.; Chlopocka-Wozniak M.; Rybakowski J.K.

Long-term efficacy of sertraline in major depression: A study with plasma levels
pp. 202-202(1)
Authors: Mauri M.C.; Scalvini M.E.; Cerveri G.; Volonteri L.; Omboni A.; Regispani F.; Laini V.; Boscati L.; Panza G.

Acute critical flicker fusion effects of serotonin reuptake inhibitors are modulated by concomitant pupillary changes
pp. 202-203(2)
Authors: Schmitt J.A.J.; Riedel W.J.; Vuurman E.F.P.M.; Kruizinga M.; Ramaekers J.G.

Shared and differential cognitive effects of serotonin reuptake inhibitors in healthy volunteers
pp. 203-203(1)
Authors: Schmitt J.A.J.; Riedel W.J.

A double blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression
pp. 203-204(2)
Authors: Williamson D.; Andersen S.; Sanger T.; Tohen M.; Van Campen L.; Corya S.; Tollefson G.

Mirtazapine in treatment of depression in patients with ischaemic heart disease
pp. 205-206(2)
Authors: Smulevich A.B.; Drobijev M.Y.; Ilina N.A.

Lamotrigine demonstrates long-term mood stabilization in bipolar patients with recent episode of mania or hypomania
pp. 206-206(1)
Authors: Calabrese J.; Montgomery S.; Akhtar S.; Hompland M.; Olajossy M.; Zieba A.; Bowden C.; Sachs G.S.; Montgomery P.; Earl N.; Greene P.

Efficacy and acceptability of tianeptine versus sertraline: A multi center, double blind, controlled study
pp. 206-206(1)
Authors: Oral E.T.; Taneli B.; Tunca Z.; Akdemir A.; Vahip S.; Dogan O.; Sofuoglu S.; Dilbaz N.; Kirpinar I.; Ulug B.; Levent B.A.; Unal S.; Ozkutlu U.

Efficacy and tolerability of sertraline in treating anxious depression
pp. 206-207(2)
Authors: Demartinis N.; Gillespie J.; Clary C.

Long-term treatment with bupropion SR effectively prevents the relapse and recurrence of depression
pp. 207-207(1)
Authors: Weihs K.; Bolden-Watson C.; Houser T.L.; Batey S.R.; Ascher J.A.; Richard N.E.; Evoniuk G.; Metz A.

A study of neuroendocrine hormones in untreated and treated women with affective disorder
pp. 207-208(2)
Authors: El Khoury A.; Tham A.; Åberg-Wistedt A.; Stain-Malmgren R.

Effectiveness of duloxetine and venlafaxine in producing increases in extracellular levels of serotonin and norepinephrine in brain
pp. 209-209(1)
Authors: Wong D.T.; Bymaster F.P.; Dreshfield-Ahmad L.

Efficacy of duloxetine, a potent and selective 5-HT/NE reuptake inhibitor, in rat models of persistent and neuropathic pain
pp. 210-210(1)
Authors: Iyengar S.; Li D.L.; Lee D.H.; Simmons R.M.A.

Fluoxetine treatment 20 mg vs 40-60 mg for pediatric fluoxetine 20 mg non-responders
pp. 210-210(1)
Authors: Heiligenstein J.H.; Hoog S.; Wagner K.; Findling R.; Ernest D.; Nilsson M.; Jacobson J.

Efficacy of intermittent fluoxetine dosing in premenstrual dysphoric disorder (PMDD)
pp. 210-210(1)
Authors: Cohen L.; Miner C.; Brown E.; Dillon J.

The risk of hospitalization for patients with bipolar disorder
pp. 210-211(2)
Authors: Bresnahan B.W.; Ling D.C.Y.; Neslusan C.A.; White A.S.; Wang S.; Crown W.H.

Duloxetine: Pharmacodynamic evidence in man of dual reuptake inhibition
pp. 211-211(1)
Authors: Chalon S.; Granier L.-A.; Vandenhende F.

AR-A000002, a high affinity 5-HT_1B receptor antagonist: Effects of subchronic treatment of guinea pigs
pp. 213-213(1)
Authors: Ross S.B.; Yu H.; Ahlgren C.; Larsson L.G.; Davidsson A.; Stenfors C.

AR-A000002, a high affinity 5-HT_1B receptor antagonist: Pharmacokinetic scaling studies
pp. 213-213(1)
Authors: Terelius Y.; Hagbjork A.L.; Stjernstrom H.; Gabrielsson J.

AR-A000002, a high affinity 5-HT_1B receptor antagonist: Synthesis and structure-activity relationships
pp. 213-214(2)
Authors: Berg S.; Hellberg S.; Linderberg M.; Nylof M.; Nordvall G.

[³H]AR-A000002, in vitro receptor binding to cloned guinea pig 5-HT_1B receptors and in vitro autoradiography in guinea pig brain
pp. 214-214(1)
Authors: Ahlgren C.; Stier S.; Radesater A.; Luthman J.; Werner T.; Strom P.; Malmberg .

AR-A00002, a high affinity 5-HT_1B receptor antagonist: Review of CNS effects in safety pharmacology studies
pp. 215-216(2)
Author: Jonasson H.

Autoradiographic studies of the 5-HT_1B/D receptors in the postmortem human brain using [³H]AR-A000002; Comparison with [³H]GR125743
pp. 216-216(1)
Authors: Hall H.; Varnas K.; Werner T.; Stenfors C.; Sedvall G.

Reboxetine, placebo and paroxetine comparison in patients with major depressive disorder: A double-blind, placebo- and comparator-controlled study
pp. 216-216(1)
Authors: Gallen C.C.; Brown M.T.; The Reboxetine Study Group

Reboxetine-associated urinary hesitancy is ameliorated by tamsulosin
pp. 217-217(1)
Authors: Demyttenaere K.; Huygens R.; Van Buggenhout R.

Reboxetine effects on cognitive functioning in depressed patients
pp. 217-217(1)
Authors: Ferguson J.; Wesnes K.; Barker K.; Schwartz G.

Behavioral effects of paroxetine and sertraline on healthy elderly volunteers
pp. 219-220(2)
Authors: Furlan P.M.; Pollock B.; Katz I.; Lucki I.

AR-A000002, a high affinity 5-HT_1B receptor antagonist: Pharmacological characterisation
pp. 220-220(1)
Authors: Stenfors C.; Yu H.; Larsson L.G.; Wallsten C.; Nilsson P.; Ross S.B.

Citalopram compared to paroxetine in depressed patients with associated anxiety
pp. 220-220(1)
Authors: Jefferson J.; Griest J.

Measuring change with antidepressant treatment in dysthymia: A comparison of rating scales
pp. 221-221(1)
Authors: Ravindran A.V.; Charbonneau Y.; Griffiths J.; Fraser J.; Anisman H.

Efficacy and tolerability of nefazodone in dysthymia without comorbid major depression
pp. 221-221(1)
Authors: Ravindran A.V.; Charbonneau Y.; Ellis J.; Zaharia M.; Wiens A.; Anisman H.

Cognitive dysfunctions in non-psychotic, recurrent, unipolar, major depression
pp. 224-224(1)
Authors: Stordal K.; Aaker E.; Lund A.

Clinical acceptability of venlafaxine extended release and paroxetine in outpatients treated for depression by general practitioners
pp. 224-225(2)
Authors: Dufour A.; Van Hauteghem D.; Slachmuylders P.; Leyman S.; Mignon A.

Age-related differences in the side effect profile of citalopram
pp. 225-225(1)
Authors: Barak Y.; Swartz M.; Weizman R.

Hypothalamic-pituitary-adrenocortical (HPA) system regulation in the long-term course of depression
pp. 225-226(2)
Authors: Hatzinger M.; Brand S.; Hemmeter U.; Baumann K.; Holsboer-Trachsler E.

Potential antidepressant-like effects of MPEP, a potent, selective and systemically active mGluR5 receptor antagonist
pp. 228-229(2)
Authors: Palucha A.; Branski P.; Kroczka B.; Wieronska J.M.; Pilc A.

Effect of combined treatment with imipramine and amantadine on the immunological parameters of rats subjected to the forced swimming test
pp. 229-229(1)
Authors: Rogoz Z.; Kubera M.; Basta-Kaim A.; Tetich M.

Sertraline in PMDD: Quality of life improvement
pp. 229-230(2)
Authors: Yonkers K.A.; Pearlstein T.; Stout A.; Gillespie J.; Harrison W.

Serum levels of citalopram and its main metabolites in adolescents treated in a naturalistic clinical setting
pp. 230-230(1)
Authors: Reis M.; Bengtsson F.

Pindolol augmentation of paroxetine: A double-blind, randomised, placebo-controlled trial of pindolol augmentation in depressive patients
pp. 230-230(1)
Authors: Geretsegger C.; Aichhorn W.; Keglevic M.; Bondy B.; Stuppaeck C.

Escitalopram has potent and rapid effect in a chronic mild stress model of depression in rats
pp. 233-233(1)
Authors: Papp M.; Sanchez C.

Sexual dysfunction among patients treated with antidepressants - A Hungarian retrospective study
pp. 233-234(2)
Authors: Osvath P.; Fekete S.; Voros V.; Tenyi T.; Vitrai J.

The influence of mirtazapine on HPA axis activity in depressive patients
pp. 234-234(1)
Authors: Schule C.; Baghai T.C.; Zwanzger P.; Minov C.; Rupprecht R.

Predicting long term outcome with sertraline and paroxetine in depressed patients
pp. 234-234(1)
Authors: Lecrubier Y.; Troy S.

Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression
pp. 234-235(2)
Authors: Minov C.; Baghai T.C.; Schule C.; Zwanzger P.; Schwarz M.J.; Zill P.; Rupprecht R.; Bondy B.

Personality traits' trending to influence outcome in bipolar disorder
pp. 236-236(1)
Authors: Laterza C.; Tagariello P.

Comparative effects of (+/-) pindolol and WAY 100635 vs beta₁ - and beta₂ - adrenergic receptor antagonists CGP 20712A and ICI 118551 on the antidepressant effect of the noradrenaline reuptake inhibitor nortriptyline
pp. 237-237(1)
Authors: Rojas-Corrales M.O.; Moreno-Brea M.R.; Berrocoso E.; Roca-Vinardell A.; Ortega-Alvaro A.; Gibert-Rahola J.; Mico J.A.

The course of depressive disorders: A dimension rather than a category
pp. 237-237(1)
Authors: Zivanovic O.; Borisev L.

Lamotrigine in bipolar depression: A clinical case series
pp. 238-238(1)
Authors: Ozerdem A.; Tunca Z.; Kaya N.

Depression in patients with chronic hepatitis C treated with interferon (IFN) - alpha therapy
pp. 238-238(1)
Authors: Quiner S.; Jessner W.; Rosenauer D.; De Zwaan M.; Ferenci P.; Kasper S.

Lithium oxybutirate effect on the circadian rhythm of lithium, sodium, calcium, potassium excretion in rats with suprachiasmatic nucleus lesion
pp. 241-241(1)
Authors: Zamoshchina T.; Meleshko M.; Ivanova E.

Suicidal ideation in a college population: Prevalence and predictors
pp. 241-242(2)
Authors: Sonawalla S.B.; Kelly K.; Neault N.; Farabaugh A.; Almeida D.; Yeung A.; Mischoulon D.; Pava J.; Otto M.; Fava M.

Adjunctive open-label topiramate in bipolar disorder
pp. 242-242(1)
Authors: Saxena S.; Fieve R.

Use of nootropic agent in memory dysfunction of lithium treated bipolar patients
pp. 242-242(1)
Authors: Malitas P.N.; Alevizos B.E.; Papadimitriou G.N.; Christodoulou G.N.

Effects on body temperature in new atypical antipsychotic drugs
pp. 245-245(1)
Authors: Degner D.; Bleich S.; Tonnies E.; Maler J.M.; Ruther E.

Perceptual category learning in healthy siblings of patients with schizophrenia
pp. 245-245(1)
Authors: Keri S.; Kelemen O.; Benedek G.; Janka Z.

Heat shock protein 70-2 genetic polymorphism in Korean patients with schizophrenia
pp. 246-246(1)
Authors: Paik I.H.; Kim J.J.; Toh K.Y.; Lee C.U.; Lee S.J.; Lee C.

Maternal immune stimulation leads to cognitive deficits in the adult offspring which are alleviated by antipsychotic treatment: A novel neurodevelopmental model of schizophrenia in the rat
pp. 246-246(1)
Authors: Zuckerman L.; Ben-Eliahu S.; Weiner I.

Striatal dopaminergic blockade and visual contrast sensitivity in patients with schizophrenia treated with quetiapine
pp. 246-246(1)
Authors: Szekeres G.; Pavics L.; Antal A.; Keri S.; Ambrus E.; Kovacs Z.; Janka Z.

Adjunctive risperidone in acute mania: A combined efficacy analysis
pp. 249-249(1)
Authors: Grossman F.; Okamoto A.; Bowden C.

Quetiapine improves mood and reduces drug cravings in bipolar, cocaine-dependent patients
pp. 250-250(1)
Authors: Brown E.S.; Nejtek V.A.; Perantie D.C.; Bobadilla L.

Safety, tolerability, and efficacy of quetiapine as adjunctive treatment for bipolar adolescents with mania
pp. 250-251(2)
Authors: DelBello M.P.; Rosenberg H.L.; Wilhoit S.R.; Seshadri V.; Strakowski S.M.

Quetiapine treatment of rapid-cycling bipolar disorder: An open prospective study
pp. 251-251(1)
Authors: Ghaemi S.N.; Goldberg J.F.; Ko J.Y.; Garno J.L.

SLV310, a molecule combining potent dopamine D₂ receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity
pp. 251-251(1)
Authors: Tuinstra T.; Herremans A.H.J.; Van der Heyden J.A.M.; McCreary A.C.; Hesselink M.B.; Kruse C.G.; Long S.K.

Risperidone plus mood stabilizer versus placebo plus mood stabilizer in patients with bipolar disorder: A combined efficacy analysis
pp. 254-254(1)
Authors: Grossman F.; Bowden C.; Okamoto A.

Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder
pp. 254-254(1)
Authors: Myers J.E.; Mahmoud R.; Berry S.; Conley R.R.

Efficacy of risperidone add-on to mood stabilizers in acute and continuation treatment of mania
pp. 255-255(1)
Author: Yatham L.N.

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: Comparison with haloperidol and risperidone
pp. 255-255(1)
Authors: Peuskens J.; Moller H.-J.

Risperidone in children with significant conduct problems and subaverage intellectual functioning
pp. 255-256(2)
Authors: Findling R.L.; Aman M.G.; De Smedt G.; Derivan A.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder
pp. 256-256(1)
Authors: Bilder R.M.; Goldman R.S.; Volavka J.; Czobor P.; Hoptman M.; Sheitman B.; Lindenmayer J.-P.; Citrome L.; McEvoy J.; Kunz M.; Chakos M.; Lieberman J.A.

Risperidone and olanzapine utilization and expenditures within the Texas Medicaid program
pp. 256-257(2)
Authors: Johnsrud M.; Crimson L.; Thompson A.; Grogg A.

Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder
pp. 257-257(1)
Authors: Harvey P.D.; Mahmoud R.; Meltzer H.Y.; Green M.P.

Serum prolactin in schizophrenia
pp. 257-257(1)
Authors: Berry S.; Martinez R.A.; Myers J.E.; Mahmoud R.

Evidence of efficacy of risperidone in schizophrenia
pp. 257-258(2)
Authors: Davis J.M.; Chen N.

Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: Results of a placebo-controlled trial with risperidone
pp. 259-260(2)
Authors: Yeung P.P.; Carson W.H.; Saha A.; McQuade R.D.; Ali M.; Stringfellow J.C.; Ingenito G.

Long-term quality-of-life and economic outcomes associated with the use of olanzapine versus divalproex for acute mania
pp. 260-261(2)
Authors: Zhu B.; Lage M.J.; Shi L.; Tunis S.; Tohen M.

Social functioning and quality of life in schizophrenia: Experience with amisulpride
pp. 261-261(1)
Authors: Olie J.P.; Stalla-Bourdillon A.

The impact of neuroleptic treatment on the quality of life of stable schizophrenic patients
pp. 261-262(2)
Authors: Arnould B.; Lehman A.F.; Ingham M.; Breand S.; Duchesne I.

Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol
pp. 262-262(1)
Authors: Nasrallah H.A.; Rennie P.; Altman C.

Preclinical studies of the effects of quetiapine on electrocardiographic measurements
pp. 265-266(2)
Authors: Duffy P.A.; Knight R.; Davis A.S.

A retrospective study of risperidone treatment outcomes: Effect and tolerabitity
pp. 266-266(1)
Authors: Wheeler A.; Robinson G.

Effects of L-type calcium channel blockers on bromocriptine-induced psychomotor sensitization
pp. 266-266(1)
Authors: Dogrul A.; Zagli U.; Yesilyurt O.; Uzbay I.T.; Isimer A.

T-type calcium channel blockade blocks bromocriptine-induced locomotor stimulation in mice
pp. 267-267(1)
Authors: Dogrul A.; Zagli U.; Yesilyurt O.

Clozapine's effect on primary negative symptoms and the initial level of symptom severity as a predictor of response
pp. 267-267(1)
Authors: Anil A.E.; Lee M.; Jayathilake K.; Meltzer H.Y.

Effects of chronic treatment with haloperidol, clozapine, olanzapine and risperidone on repetitive jaw movements (RJM) in rat model of tardive dyskinesia
pp. 269-270(2)
Authors: Rosengartner H.; Quartermain D.

Safety of olanzapine at doses higher than 20 mg/day versus typical antipsychotics in the treatment of schizophrenic in-patients (EUROPA study)
pp. 270-270(1)
Authors: Gascon J.; Ciudad A.; Alvarez E.; Bobes J.; Canas F.; Carrasco J.L.; Gibert J.; Gomez J.C.; Gutierrez M.

Comparison of hospital stays due to a relapse of schizophrenia in Germany by means of hospital chart review: Olanzapine versus haloperidol
pp. 270-271(2)
Authors: Spannheimer A.; Reitberger U.; Clouth J.; Ralston S.

Recent weight gain and the cost of acute service use among individuals with schizophrenia
pp. 271-271(1)
Authors: Weiden P.J.; Mackell J.A.; McDonnell D.D.

The costs and consequences of switching patients from typical antipsychotics to quetiapine
pp. 271-272(2)
Authors: Das Gupta R.; Russ J.; Guest J.F.

Pharmacokinetics of intramuscular (IM) ziprasidone in healthy volunteers
pp. 273-274(2)
Authors: Miceli J.J.; Wilner K.D.; Tensfeldt T.G.

Ziprasidone vs olanzapine in schizophrenia: Results of a double-blind trial
pp. 274-274(1)
Authors: Simpson G.; O'Sullivan R.L.; Siu C.

Increased cardiovascular disease in patients with schizophrenia
pp. 274-274(1)
Authors: Curkendall S.; Mo J.; Jones J.K.; Glasser D.

FOCIS: An international survey on cognitive dysfunction in schizophrenia
pp. 274-275(2)
Authors: Gallhofer B.; Green M.P.; Barnes T.; Danion J.-M.; Meltzer H.Y.; Pantelis C.

Ziprasidone vs haloperidol in sequential IM/oral treatment of acute schizophrenia
pp. 275-275(1)
Author: Brook S.

Exploration of a dose-response relationship in schizophrenia with the novel antipsychotic drug olanzapine
pp. 278-278(1)
Authors: Kinon B.J.; Wang L.; Gilmore J.A.

The efficacy of olanzapine plus adjunctive lorazepam to control acute agitation in schizophrenia
pp. 278-278(1)
Authors: Kinon B.J.; Wang L.; Rotelli M.D.; Gilmore J.A.

Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol, and placebo
pp. 278-279(2)
Authors: Baker R.W.; Juliar B.E.; Stauffer V.L.

Nizatidine may ameliorate weight gain during olanzapine treatment
pp. 279-279(1)
Authors: Breier A.; Tanaka Y.; Roychowdhury S.; Clark W.S.

Regional CBF changes with risperidone in schizophrenic patients: Comparison with haloperidol
pp. 281-282(2)
Authors: Gonul A.S.; Kula M.; Oguz A.; Tutus A.; Yabanoglu I.; Sofuoglu S.

The effects of ECT on CSF levels of HVA and 5-HIAA in drug-naive schizophrenic patients
pp. 282-282(1)
Authors: Oguz A.; Tangor A.; Gonul A.S.

Characterization of dopamine receptor of type 4 (D4) in human frontal cortex post-mortem
pp. 282-283(2)
Authors: Marazziti D.; Masala I.; Giannaccini G.; Di Nasso E.; Betti L.; Lucacchini A.; Baroni S.

Effects of classical and atypical antipsychotics on hypothalamic-pituitary-thyroid axis in schizophrenic patients
pp. 283-283(1)
Authors: Esel E.; Sofuoglu S.; Kula M.; Turan M.T.; Izgi H.B.

Treatment-induced changes in factorial structure of schizophrenia
pp. 283-283(1)
Authors: Loza B.; Kucharska-Pietura K.

Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on WCST and dichotic listening scores
pp. 285-286(2)
Authors: Loza B.; Kucharska-Pietura K.; Debowska G.

Costs of schizophrenia care associated with olanzapine, risperidone, or haloperidol in a public mental health system
pp. 286-286(1)
Authors: Damler R.; Jackson E.A.; Wilder T.; Gibson P.J.; Ramsey J.L.; Edgell E.

Atypical antipsychotics' use among acute schizophrenic inpatients
pp. 286-287(2)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Kollias C.T.; Margariti M.M.; Stamouli S.S.; Christodoulou G.N.

Does the intracellular signalling system associated to the serotonergic 5-HT_2A receptor activation predict clinical response to olanzapine in drug-free schizophrenic patients?
pp. 287-287(1)
Authors: Arranz B.; Ramirez N.; Duenas R.; Cano R.; Gonzalez J.M.

Lymphocyte subsets in acute psychotic schizophrenic patients
pp. 287-288(2)
Authors: Aksaray G.; Gulbas Z.; Kaptanoglu C.; Demirel G.; Ozaltin M.

Anticipation in schizophrenia: Age at onset, psychosocial functioning and treatment response across generations
pp. 290-291(2)
Authors: Zivanovic O.; Borisev L.; Lalic B.

Another aspect of anticipation in schizophrenia: Suicide attempts in successive generations
pp. 291-291(1)
Authors: Zivanovic O.; Borisev L.

Cognitive disfunction in schizophrenia depends partially on short-term and delayed plasticity changes in schizophrenia, as reflected in mismatch negativity potentials
pp. 291-291(1)
Authors: Hirsch S.R.; Baldeweg T.; Krljes S.; Faruqui R.A.

Long-acting risperidone microspheres for treatment of patients with schizophrenia
pp. 292-292(1)
Authors: Kane J.; Eerdekens M.; Keith S.; Lesem M.; Karcher K.; Lindenmayer J.P.

Lack of weight gain during amisulpride treatment
pp. 292-292(1)
Author: Mahe V.

Fronto-temporal disconnection and negative symptoms in schizophrenia
pp. 295-296(2)
Authors: Canive J.M.; LaNoue M.; Heller W.; Edgar J.C.; Miller G.A.

No effect of reboxetine on plasma concentrations of clozapine, risperidone and their active metabolites in patients with schizophrenia
pp. 296-296(1)
Authors: Spina E.; Avenoso A.; Scordo M.G.; Ancione M.; Madia A.G.; Levita A.

Are schizophrenia and antipsychotic treatment risk factors for osteoporosis?
pp. 296-296(1)
Authors: Hummer M.; Gasser R.; Hofer A.; Kemmler G.; Malik P.; Oehl M.; Fleischhacker W.W.

Preclinical studies of the effects of quetiapine on electrocardiographic measurements
pp. 296-297(2)
Authors: Duffy P.A.; Knight R.; Davis A.S.

Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia
pp. 298-298(1)
Authors: Zanardini R.; Bocchio Chiavetto L.; Boin F.; Tura G.B.; Bignotti S.; Michelato A.; Popoli M.; Racagni G.; Altamura C.A.; Gennarelli M.

Anxiolytic action of atrial natriuretic hormone on panic attacks induced by cholecystokinin tetrapeptide
pp. 298-299(2)
Authors: Kellner M.; Yassouridis A.; Holsboer F.; Wiedemann K.

Oral morphine in treatment resistant obsessive-compulsive disorder (OCD)
pp. 299-299(1)
Authors: Koran L.M.; Franz B.; Bullock K.D.; Elliot M.A.

Adequacy of pharmacotherapy in obsessive compulsive disorder: Data on 200 outpatients
pp. 302-302(1)
Authors: Denys D.; Van Megen H.G.M.; Westenberg H.G.M.

Clinical characteristics of obsessive-compulsive disorder: A sample of 300 OCD-outpatients
pp. 302-302(1)
Authors: Denys D.; De Geus F.; Van Megen H.G.M.; Westenberg H.G.M.

Citalopram treatment of children and adolescents with obsessive-compulsive disorder: A preliminary report
pp. 302-302(1)
Authors: Mukaddes N.; Abali O.; Kaynak N.

The effects of repeated pentylenetetrazol administration on rat emotional behavior
pp. 303-303(1)
Authors: Szyndler J.; Maciejak P.; Sienkiewicz-Jarosz H.; Czlonkowska A.; Siemiatkowski M.; Plaznik A.

¹²³I Beta-CIT SPECT of dopamine and serotonine transporters in obsessive compulsive disorder
pp. 303-303(1)
Authors: Van der Wee N.; Stevens H.; Harmelink M.; Van Megen H.G.M.; Van Rijk P.; Westenberg H.G.M.

Assessment of potential interaction between naloxone and diazepam in anxious subjects
pp. 303-304(2)
Authors: Prosperi A.; Micallef J.; Dubreuil D.; Bruguerolle B.; Blin O.

Paroxetine in the treatment of post-traumatic stress disorder (PTSD)
pp. 306-306(1)
Authors: Davidson J.R.T.; Stein D.; Hewett K.; Adams A.; Bryson H.; Beebe K.; Pitts C.; Ruggerio L.

Perception of post traumatic stress disorder amongst practitioners
pp. 306-306(1)
Author: Jenner P.

AR-A000002, a high affinity 5-HT_1B receptor antagonist: Evaluation of its anxiolytic potential
pp. 307-307(1)
Authors: Ryan C.; Hudzik T.J.; Yanek M.; Porrey T.; Evenden J.; Paronis C.; Mastrangelo M.; Ross S.B.; Stenfors C.

Paroxetine treatment of generalised anxiety disorder (GAD): Remission status
pp. 307-307(1)
Authors: Stocchi F.; Nordera G.; Jokinen R.; Lepola U.

Impact of affective and anxiety comorbidity on the clinical presentation of PTSD and its response to sertraline
pp. 308-308(1)
Authors: Brady K.; Friedman M.; Gaffney M.; Clary C.M.

Are agmatine and harman endogenous antidepressant/anxiolytic compounds?
pp. 308-308(1)
Authors: Aricioglu-Kartal F.; Altunbas H.

Olanzapine augmentation in refractory obsessive compulsive disorder: An open-label study
pp. 310-310(1)
Authors: Corretti G.; Abelli M.; Pfanner C.; Gemignani A.; Ciapparelli A.; Marazziti D.; Dell'Osso L.; Cassano G.B.

Citalopram in refractory OCD patients
pp. 310-311(2)
Authors: Marazziti D.; Di Nasso E.; Masala I.; Gemignani A.; Pfanner C.; Presta S.; Dell'Osso L.; Cassano G.B.

Anxiolytic-like effects of CGP 36742 an antagonist of GABA_B receptors in animal models
pp. 311-311(1)
Authors: Klodzinska A.; Chojnacka-Wojcik E.; Pilc A.

Relationships between clinical symptoms and cerebrospinal fluid levels of neurotransmitters in panic disorder patients
pp. 311-311(1)
Authors: Gunnarsson T.; Sjodin I.

Escitalopram shows potent anxiolytic activity in the dorsal peri-aqueductal grey stimulation model
pp. 311-312(2)
Authors: Hogg S.; Lapiz M.D.S.; Jessa M.

Alternative route of administration and titration of SRIs in anxious resistant patients: Two day-hospital experiences
pp. 312-312(1)
Authors: Pallanti S.; Quercioli L.

Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults
pp. 314-314(1)
Authors: Frackiewicz E.J.; Tigel P.D.

The ontogenetic aspects of food-derived opioid peptide -casomorphin-7 anxiolytic influence
pp. 314-314(1)
Authors: Ivleva I.A.; Vylegzanina A.V.; Malinovskaia I.V.; Andreeva L.A.; Dubynin V.A.

Buspirone prevents sexual motivation in depressed male mice from reduction
pp. 314-315(2)
Authors: Amikishieva A.V.; Avgustinovich D.F.; Koryakina L.A.

Double blind study on withdrawal syndrome in chlordemethyldiazepam long-term users
pp. 315-315(1)
Authors: Porrini A.M.; The Italian study group on benzodiazepine withdrawal syndrome

Olfactory precipitation of PTSD symptoms in combat veterans with chronic PTSD: Preliminary findings of a pet study
pp. 315-316(2)
Authors: Vermetten E.; Palumberi H.D.; Siddig S.; Southwick S.M.; Greer C.; Bremner J.D.

Pregnancy, delivery and infancy complications (PDICs) as risk factors of attention-deficit hyperactivity disorder (ADHD), a specific comparison with child psychiatric controls
pp. 316-316(1)
Authors: Csorba J.; Rozsa S.; Kaczvinszky E.; Kapornay K.

Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial
pp. 318-319(2)
Authors: Dittmann R.W.; Fouche D.S.; Kratochvil C.; Heiligenstein J.H.; Spencer T.; Biederman J.

Safety of atomoxetine in pediatric patients treated for ADHD
pp. 319-319(1)
Authors: Wernicke J.F.; Fouche D.S.; Spencer T.; Dunn D.; Faries D.E.; Kelsey D.K.; Heiligenstein J.H.; Michelson D.

Atomoxetine in the treatment of children with ADHD: A randomized, placebo-controlled dose-response study
pp. 319-320(2)
Authors: Michelson D.; Faries D.E.; Wernicke J.F.; Spencer T.

Long-term memory and mood effects of donepezil in affective illness
pp. 320-320(1)
Authors: Jacobsen F.M.; Comas-Diaz L.

Dementia accompanying motor neuron disease - 7 cases
pp. 320-321(2)
Authors: Marquard R.; Muller R.; Wada M.; Kurz A.

Donepezil compared to rivastigmine in Alzheimer's disease: Similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial
pp. 321-321(1)
Authors: Hock C.; Wilkinson D.G.; Passmore P.; Bullock R.; Hopker S.W.; Smith R.; Potocnik F.C.V.; Maud C.M.; Englebrecht I.; Mastey V.; Bahra R.; Schwam E.; Ieni J.

Effect of naloxone treatment on ATP-ase's activities of synaptic plasma membranes from rat hippocampus
pp. 321-322(2)
Authors: Villa R.F.; Devecchi E.; Gorini A.

Favorable anticholinergic profile of olanzapine in elderly patients with dementia
pp. 323-324(2)
Authors: Kinon B.J.; Stauffer V.L.; Wang L.; Kennedy J.S.

Glutamate levels in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. A reappraisal using a new HPLC method with coulometric detection in a large cohort of patients
pp. 324-324(1)
Authors: Spreux-Varoquaux O.; Lacomblez L.; Bensimon G.; Salachas F.; Dib M.; Marouan A.; Julien P.; Pradat P.F.; LeForestier N.; Meininger V.

Role of CYP2D1 in the metabolism and elimination of the parkinsonism inducing compound 1,2,3,4,-tetrahydroisoquinoline in the rat
pp. 324-324(1)
Authors: Lorenc-Koci E.; Wojcikowski J.; Kot M.; Daniel W.A.

The use of typical and atypical neuroleptics for controlling behavioral disturbances in dementia: A retrospective study
pp. 324-325(2)
Authors: Ballesteros J.; Martin M.; Lopez de Argumedo M.; Garcia C.; Blanco F.J.; De Blas J.; Baraibar G.; Minguez L.; Aguero J.A.

The effect of single 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MTIQ) administration on concentration of noradrenaline and dopamine in the mouse and rat brain
pp. 325-325(1)
Authors: Antkiewicz-Michaluk L.; Karolewicz B.; Romanska I.; Vetulani J.

Significant improvements in symptoms in patients with 'advanced moderate' AD during galantamine treatment
pp. 325-326(2)
Authors: Kurz A.; Schwalen S.

Mental deterioration and behavioural disorders in progressive myoclonus epilepsy
pp. 327-328(2)
Authors: Paneva G.; Jovic N.; Cuk D.

Diurnal fluctuations of aldehyde dehydrogenase in the brain regions of rats and ethanol effects on it
pp. 328-328(1)
Authors: Satanovskaya V.; Bardina L.

Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease
pp. 328-328(1)
Authors: Bullock R.; Moulias R.; Steinwachs K.C.; Cicin-Sain A.; Spiegel R.

Statins in the treatment of Alzheimers Disease
pp. 328-329(2)
Authors: Winblad B.; Carlsson L.A.; Crisby M.

Plasma beta-endorphin and withdrawal-induced anxiety in alcoholism
pp. 329-329(1)
Authors: Kiefer F.; Horntrich M.; Jahn H.; Arlt J.; Kampf P.; Wolf K.; Wiedemann K.

Gender differences in the psychotropic effects of MDMA (''Ecstasy'')
pp. 329-330(2)
Authors: Liechti M.E.; Gamma A.; Vollenweider F.X.

The effects of the nitric oxide synthase inhibitor 7-nitroindazole on the behaviour of mice after chronic and acute ethanol administration
pp. 332-332(1)
Authors: Pokk P.; Sepp E.; Vassiljev V.; Vali M.

An opiate receptor antagonist, antaxone, influences dopamine system functions in morphine dependent rats
pp. 333-333(1)
Authors: Anokhina I.P.; Veretinskaya A.G.; Vasilieva G.N.; Shamakina I.Y.

French alcohol-dependent inpatients' attitudes about smoking cessation
pp. 333-333(1)
Authors: Gillet C.; Tenette A.L.; Pirollet P.; Toussaint S.; Paille F.

The use of psychoactive drugs and physical status of opiate dependent patients before and after one year of participation in methadone program
pp. 334-334(1)
Authors: Habrat B.; Chmielewska K.; Baran-Furga H.

Assessment of route navigational memory in actual city traffic as a measure of attentional capacity under the influence of drugs: Rationale and application of a new test
pp. 334-334(1)
Authors: Riedel W.J.; Schmitt J.A.J.; Lamers C.T.J.; Ramaekers J.G.

Maintenance therapy with synthetic opioids and driving aptitude
pp. 336-336(1)
Authors: Schindler S.-D.; Eder H.; Peternell A.; Ortner R.; Kraigher D.; Opgenoorth E.; Fischer G.

Rapid opiate detoxification under general anesthesia (RODA): Preliminary results of the CHU of Liege
pp. 337-337(1)
Authors: Pinto E.; Reggers J.; Fuchs S.; Pitchot W.; Hansenne M.; Ansseau M.

Use of olanzapine to reduce cocaine consumption in methadone maintenance programmes
pp. 337-338(2)
Authors: Landabaso M.A.; Iraurgi I.; Calle R.; Jimenez-Lerma J.M.; Hormaechea J.A.

Predictors for early drop-out in a strict inpatient opiate withdrawal regimen
pp. 338-338(1)
Authors: Heiden A.; Frey R.; Presslich O.; Frottier P.; Willinger U.; Blasbichler T.; Kasper S.

Analysis of genetic polymorphism of dopamine D₃ and serotonin 5-HT2a receptor genes in the Korean schizophrenics
pp. 338-338(1)
Authors: Kim Y.W.; Hahn H.M.; Han J.Y.; Choe B.M.

Behavioural symptoms in chronic schizophrenics
pp. 338-339(2)
Authors: Henry M.; Morera A.L.; Garcia-Hernandez A.; Frugoni A.; Gracia R.

Systemic and carotid haemodynamic effects of the novel 5-HT_1B/1D receptor agonist donitriptan in anaesthetised pigs
pp. 340-341(2)
Authors: Tom B.; De Vries P.; Heiligers J.P.C.; Willems E.W.; Kapoor K.; Saxena P.R.

The role of social factors and the change in drinking in the outcome of alcoholic hallucinosis
pp. 341-341(1)
Authors: Gati A.; Trixler M.; Tenyi T.

A microdialysis study of (R)-8-OH-DPAT transport across the blood-brain barrier in rats - Pharmacokinetic considerations in blood and brain regions
pp. 343-343(1)
Authors: Yu H.; Lewander T.; Hammarlund-Udenaes M.

The significance of psychoconstitution-pharmacokinetics correlation for optimizing psychopharmacotherapy
pp. 343-344(2)
Authors: Bayanov A.; Brunt A.

Individual susceptibility to phenobarbital and carbamazepine in epileptic patients with different psychovegetative reactivity
pp. 344-344(1)
Authors: Paramonova E.; Bayanov A.; Koroleva S.

5-HT2A T 102C gene polymorphism in Turkish patients with obsessive compulsive disorder
pp. 344-344(1)
Authors: Tot S.; Erdal M.E.; Yazici K.; Herken H.; Yazici A.; Bal N.

Serotonin transporter gene polymorphism in Turkish patients with obsessive compulsive disorder
pp. 344-345(2)
Authors: Tot S.; Erdal M.E.; Yazici K.; Herken H.; Yazici A.; Metin O.

Catechol-O-methyl transferase gene polymorphism in Turkish patients with obsessive compulsive disorder
pp. 345-345(1)
Authors: Erdal M.E.; Tot S.; Herken H.; Yazici K.; Yazici A.; Erdem P.

REM sleep suppression in patients with obstructive sleep apnea: Effects of REM suppressing medication
pp. 347-347(1)
Authors: Baran A.S.; Richert A.C.; Ansarin K.; Roffwarg H.P.; Halaris A.

Milnacipran in the treatment of bulimia: A report of 16 cases
pp. 347-348(2)
Authors: El-Giamal N.; De Zwaan M.; Bailer U.; Strnad A.; Schussler P.; Kasper S.

A new model for assessment of stimulus processing and behavior control in humans following experimental induction of emotions
pp. 348-348(1)
Authors: Fischer C.J.; Wendorff T.; Fritzer G.; Lemke M.R.; Rupp Z.; Tetzlaff S.

Structural MRI findings in child autism
pp. 348-349(2)
Authors: Hrdlicka M.; Propper L.; Lisy J.; Belsan T.; Blatny M.; Urbanek T.

Are hexosaminidase enzymes related with extrapyramidal symptoms and psychopathology in mental disorders?
pp. 349-349(1)
Authors: Tunca Z.; Resmi H.; Ozkara A.; Ciliv G.; Celtikci B.; Alptekin K.; Ozerdem A.; Kivircik B.; Baykara B.; Tunca B.; Ergor G.

Effects on actual car driving performance of the selective H1-antagonists, emedastine and cetirzine, alone and with alcohol
pp. 349-350(2)
Authors: Vermeeren A.; Ramaekers J.G.; O'Hanlon J.F.

Impact of amisulpride on health care resources: The Oasis study
pp. 351-352(2)
Authors: Olie J.P.; Levy E.; Carita P.; Spiesser J.

L-type and T-type calcium channel blockers potentiate the antinociceptive effects of morphine and selective mu opioid agonist, but not to delta and kappa agonist at the level of the spinal cord
pp. 352-352(1)
Authors: Dogrul A.; Yesilyurt O.; Isimer A.; Guzeldemir M.E.

Effects of neomycin on the development of tolerance to morphine antinociception
pp. 352-353(2)
Authors: Dogrul A.; Yesilyurt O.; Isimer A.

Different effects of L-type calcium channel blockade on pentlyentetrazole seizures in mice
pp. 353-353(1)
Authors: Dogrul A.; Yesilyurt O.; Uzbay I.T.

Insight and response to treatment in obsessive compulsive disorder: Relationship with cognitive performance
pp. 353-354(2)
Authors: Boldrini M.; Murciano L.; Nieri M.; Placidi G.P.A.; Placidi G.F.

The effect of agmatine on lipid peroxidation and glutathione in mice brain
pp. 354-354(1)
Authors: Sener G.; Altunbas H.; Aricioglu-Kartal F.

Distribution of the [³H]-GR65630 binding in human brain postmortem
pp. 356-356(1)
Authors: Marazziti D.; Betti L.; Giannaccini G.; Baroni S.; Masala I.; Cassano G.B.; Lucacchini A.

The influence of substitution in the aromatic part of 1,2,3,4-tetrahydroisoquinoline on 5-HT_1A/5-HT_2A receptor activities of its 1-adamantoiloaminoalkyl derivatives
pp. 356-356(1)
Authors: Wesolowska A.; Mokrosz M.J.; Charakchieva-Minol S.; Tatarczynska E.; Klodzinska A.

Reduced postexercise facilitation of motor evoked potentials to transcranial magnetic stimulation in medicated psychiatric patients
pp. 356-357(2)
Authors: Chroni E.; Lekka N.P.; Tsoussis I.; Paschalis C.; Beratis S.

Cognitive functions in hyperthyroid patients
pp. 357-357(1)
Authors: Suwalska A.; Lacka K.; Borkowska A.; Lojko D.; Bolko P.; Rybakowski J.K.

Methods in suicide attempts - Characteristics of overdoses in the sample of Pecs Centre, Hungary, in WHO/EURO Multicentre Study on Suicidal Behavior, 1997-2000
pp. 357-358(2)
Authors: Fekete S.; Osvath P.; Voros V.; Trixler M.

An investigation of the mechanism responsible for the proconvulsant effect of caffeine in mice
pp. 358-358(1)
Authors: Lightowler S.; McNicoll C.; Upton R.; Wadsworth G.; Weiss S.

Prepulse inhibition: Age- and gender-effects in healthy comparisons
pp. 358-359(2)
Authors: Ludewig K.; Ludewig S.; Seitz A.; Obrist M.; Vollenweider F.X.

5-HT1A dysfunction in borderilne personality disorder
pp. 360-361(2)
Authors: Hansenne M.; Pitchot W.; Pinto E.; Reggers J.; Scantamburlo G.; Fuchs S.; Pirard S.; Ansseau M.

Insight in patients with bipolar disorder with comorbid panic disorder, social phobia and obsessive compulsive disorder
pp. 361-361(1)
Authors: Pini S.; Dell'Osso L.; Amador X.F.; Soldani F.; Mastrocinque C.; Saettoni M.; Papasogli A.; Vignoli S.; Cassano G.B.

Tolerance to the anxiogenic and hypolocomotor effects of various 5-HT_2C receptor agonists
pp. 361-362(2)
Authors: Goetghebeur P.; Lightowler S.; Bickerdike M.J.; Kennett G.A.

Menstrually related symptom changes in women with bipolar disorder - A preliminary report
pp. 362-362(1)
Authors: Karadag F.; Akdeniz P.; Erten E.; Pirildar S.

One year follow-up in parasuicidal patients
pp. 362-363(2)
Authors: Fernandez C.; Saiz P.A.; Gonzalez M.P.; Gonzalez J.C.; Ramos Y.; Bobes J.

The effects of the L-type VDCC blockers at the neuromuscular junction
pp. 363-363(1)
Authors: Nurten A.; Kara I.; Ozerman B.; Koyuncuoglu H.

Attention deficit hiperactivity disorder (ADHD) in adults: Demographic caracteristics, comorbidity and treatment
pp. 365-365(1)
Authors: Louza M.; Monteiro M.A.; Xavier J.C.; Yeh M.

The use of herbal remedies among psychiatric outpatients
pp. 365-366(2)
Authors: Haddad P.; Warrington S.; Parveen R.; Singh Y.; Gates M.

Personality dimensions in patients with CFS who were depressed compared to patients with depressive illness
pp. 366-366(1)
Authors: Schlogelhofer M.; Itzlinger U.; Barth A.; Konnaris C.; Wolf C.; Aschauer H.N.

Adult psychiatric outcome of ADHD-children. A 15-30 year follow-up study of 208 children treated with stimulants
pp. 366-366(1)
Authors: Dalsgaard S.; Mortensen P.B.; Thomsen P.H.

Thyroid functions in lithium-treated patients
pp. 367-367(1)
Authors: Kulan E.; Ozpoyraz N.; Tamam L.

Tryptophan depletion in bulimia nervosa
pp. 367-367(1)
Authors: Bailer U.; Leisch F.; Schussler P.; El-Gaimal N.; Strnad A.; Hornik K.; Kasper S.; De Zwaan M.

Right cerebral hemisphere advantage in perception of vocal affect in schizophrenia
pp. 370-370(1)
Authors: Kucharska-Pietura K.; Klimkowski M.; Loza B.

Author index
pp. 371-380(10)

Keyword index
pp. 381-384(4)